Undeterred by Novo Nordisk failure, scientists consider GLP-1s as Alzheimer’s prevention

  • Post author:
  • Post category:News

CHICAGO, Nov 25 (Reuters) – Novo Nordisk’s (NOVOb.CO), opens new tab highly anticipated but ultimately unsuccessful Alzheimer’s trials were a long shot for the maker of blockbuster drugs Ozempic and Wegovy, but scientists are still asking if GLP-1 drugs should be tested to prevent the disease in people at risk.

Full Story